trial

Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia

NCTId NCT04094207
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 80 (actual)
Sponsored by Sadat City University
Primary completion 2021-09-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
80 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2019-01-01
Primary completion
2021-09-30
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Pentoxifylline

Sponsors

Sadat City UniversityLead Sponsor

Sites

1 total
Shibīn al Kawm, Egypt

Linked catalysts

1
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Sch — primary completion2021-09-30

Facts & assertions

4 sourced
Enrollment
80
Phase
PHASE1,PHASE2
Primary Completion Date
2021-09-30
Status
COMPLETED
relationships
The graph out of here
drug
Pentoxifylline
drug
lead_sponsor
Sadat City University
company
indication
Schizophrenia
indication
Schizophrenia
indication